Steven W Larson

US Patent:

6451995, Sep 17, 2002

Filed:

Sep 18, 1998

Appl. No.:

09/142974

Inventors:

Steven M. Larson - Washington DC
Ken Rivlin - New York NY
Michel Sadelain - New York NY

Assignee:

Sloan-Kettering Institute for Cancer Research - New York NY

International Classification:

C12N 1513

US Classification:

536 2353, 5303873, 53038885

Abstract:

Recombinant antibody constructs comprise the variable regions of the heavy and light chains of anti-G antibodies. These antibody constructs may be coupled to a label such as a radiolabel or to a protein such as streptavidin or pro-drug converting enzymes for use in imaging or therapeutic applications. The antibody constructs may also be transduced into T cells to produce populations of T cells which target G -producing tumor cells.

US Patent:

20030147808, Aug 7, 2003

Filed:

Feb 13, 2002

Appl. No.:

10/075947

Inventors:

Steven Larson - Washington DC, US
Ken Rivlin - New York NY, US
Michel Sadelain - New York NY, US

International Classification:

A61K051/00
G01N033/574
C07H021/04
C12P021/02
C12N005/06
C07K016/30
A61K039/395

US Classification:

424/001490, 435/069100, 435/320100, 530/388220, 530/391100, 536/023530, 435/334000, 435/007230, 424/143100

Abstract:

Recombinant antibody constructs comprise the variable regions of the heavy and light chains of anti-Gantibodies. These antibody constructs may be coupled to a label such as a radiolabel or to a protein such as streptavidin or pro-drug converting enzymes for use in imaging or therapeutic applications. The antibody constructs may also be transduced into T cells to produce populations of T cells which target G-producing tumor cells.

US Patent:

47757590, Oct 4, 1988

Filed:

Nov 27, 1984

Appl. No.:

6/675276

Inventors:

Kenner C. Rice - Rockville MD
Candace B. Pert - Bethesda MD
Terrence R. Burke - West Bethesda MD
Steven M. Larson - Cabin John MD
William C. Eckelman - Rockville MD
Michael A. Channing - Annapolis MD

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

A61K 4300
A61K 4902
C07D48908

US Classification:

546 44

Abstract:

Fluorinated derivatives 3,14-dihydroxy-4,5. alpha. -epoxy-6. beta. -fluoro-17-methylmorphinan ("fluorooxymorphone"; FOXY, compound 10) and 17-cyclopropylmethyl-3,14-dihydroxy-4,5. alpha. -epoxy-6. beta. -fluoromorphin an (CYCLOFOXY, compound 18) are prepared based upon the structures of the potent opioid agonist oxymorphone 4 and the antagonist naltrexone 11, respectively. Fluorine was introduced in the final stages of synthesis by a facile nucleophilic displacement with fluoride ion of the 6. alpha. -triflate functions in 8 and 16. The synthetic procedures were suitable for the production of the corresponding positron emitting. sup. 18 F-labeled analogs. sup. 18 F-FOXY and. sup. 18 F-CYCLOFOXY, which are useful for in vivo studies of the opioid receptor system using positron emission transaxial tomography. In addition, the tritiation of FOXY (10) to high specific activity is noted.

US Patent:

51851423, Feb 9, 1993

Filed:

Jul 28, 1989

Appl. No.:

7/386095

Inventors:

Steven M. Larson - Washington DC
Ronald Finn - Bethesda MD
Jorge A. Carrasquillo - Rockville MD
James C. Reynolds - Rockville MD
Ronald D. Neumann - Potomac MD
Martin C. Graham - Larchmont NY
Keith S. Pentlow - Forest Hills NY

Assignee:

The United States of America as represented by the Secretary of the
Department of Health and Human Services - Washington DC

International Classification:

A61K 4902
C07K 1500

US Classification:

424 11

Abstract:

A composition comprises an antigen-specific antibody or antigen-binding fragment thereof labeled with Iodine-124 at a site other than, and which does not significantly interfere with, the antibody-antigen binding site. An in vivo method of radiotherapy directed to an antigenic site comprises administering to a subject in need of the therapy an amount of the antigen-specific composition described above effective to attain a reduction of the size of a tumor associated with the antigen. An in vivo method for detecting and localizing an antigenic site in a subject in need of such detection comprises administering to the subject an amount of the antigen-specific composition of the invention effective to localize the antigen-antibody binding site and scanning the subject's body with a positron-emitter detector to attain the localization of the site. An in situ method of radiotherapy directed to an antigenic site in a subject in need of such therapy comprises detecting and localizing the site by the in vivo method described above and thereafter in situ delivering a positron-emitting labeled antibody chelate capable of binding to either the I-124 labeled antibody or fragment thereof, or to the antigen at a site other than the antibody-antigen binding site.

Author:

Steven M. Larson

ISBN #:

0387488936

Author:

Steven M. Larson

ISBN #:

0397513755

Author:

Steven M. Larson

ISBN #:

0801649447

Author:

Steven B. Larson

ISBN #:

0070364893

Author:

Steven B. Larson

ISBN #:

0070364915

Author:

Steven J. Larson

ISBN #:

0756721806